2022 Fiscal Year Final Research Report
Assessment of the utility of KATNAL2 as a therapeutic target in lung cancer stem cells
| Project/Area Number |
20K07581
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50010:Tumor biology-related
|
|---|
| Research Institution | Kindai University (2022)
Aichi Cancer Center Research Institute (2020-2021) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 肺腺がん / 一次線毛 |
|---|
| Outline of Final Research Achievements |
This study for KATNAL2 (katanin catalytic subunit A1 like 2), newly identified ciliogenesis-regulating protein in lung adenocarcinoma cells, has been performed to assess its involvement in cancer stemness as well as its utility as a therapeutic target. We found that ciliated A549 cells show cell cycle arrest at a different point from quiescent cancer stem cells staying at G0-G1 arrest. Furthermore, coincidence was not observed between ciliary marker expression and cancer stem cell marker expression. Knockout of the KATNAL2 gene inhibited ciliary extension and increased the sensitivity to some anticancer agents targeting cell proliferation. These results suggest a potential effect of KATNAL2-targeted drug when used in combination with currently-used agents.
|
| Free Research Field |
腫瘍生物学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究成果の意義は大きく分けて2つある。1つめは学術的な意義である。少なくとも肺腺がんにおいて、がん幹細胞以外に細胞周期が静止し続ける細胞分画が存在し、その静止の分子メカニズムにKATNAL2(katanin catalytic subunit A1 like 2)が関与する可能性が示唆された。2つめは実用化に関する意義である。KATNAL2を標的とする分子標的薬を開発し、既存の抗腫瘍薬と併用することで、治療効果を高められる可能性が示唆された。
|
